Grassi Investment Management’s Fate Therapeutics FATE Stock Holding History

Grassi Investment Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$20K	Hold	18,000	–	–	﹤0.01%	127
2025 Q1	$14K	Hold	18,000	–	–	﹤0.01%	121
2024 Q4	$30K	Hold	18,000	–	–	﹤0.01%	129
2024 Q3	$63K	Hold	18,000	–	–	0.01%	126
2024 Q2	$59K	Hold	18,000	–	–	0.01%	127
2024 Q1	$132K	Hold	18,000	–	–	0.01%	122
2023 Q4	$67K	Hold	18,000	–	–	0.01%	121
2023 Q3	$38K	Hold	18,000	–	–	﹤0.01%	122
2023 Q2	$86K	Hold	18,000	–	–	0.01%	124
2023 Q1	$103K	Buy	+18,000	New	+$109K	0.01%	125

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Grassi Investment Management's FATE Position: Q2 2025 in Review

Grassi Investment Management held its Fate Therapeutics (FATE) position steady in Q2 2025 at 18,000 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #127.

Grassi Investment Management first reported a position in FATE in Q1 2023 and has held it in 10 quarters since. The position peaked at $132K in Q1 2024. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

Grassi Investment Management held 18,000 shares of Fate Therapeutics worth $20K as of Q2 2025.
Grassi Investment Management left its Fate Therapeutics share count unchanged in Q2 2025.
Fate Therapeutics made up ﹤0.01% of Grassi Investment Management's portfolio in Q2 2025, its #127 holding.
Grassi Investment Management first reported a position in Fate Therapeutics in Q1 2023 and has held it in 10 quarters since.
Grassi Investment Management's Fate Therapeutics position peaked at $132K in Q1 2024.
139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on Grassi Investment Management's 13F filing for Q2 2025, filed 21 Jul 2025.